Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Glioblastoma Multiforme Patients Undergoing Postneurosurgical Radiotherapy Plus Concurrent and Adjuvant Temozolomide

Table 3

Results of uni- and multivariate analysis.

Variable	PFS			OS
	Univariate; value	Multivariate; value	Hazard ratio	Univariate; value	Multivariate; value	Hazard ratio
Age (≤50 vs. >50 years)	0.17	—	—	0.14	—	—
Gender (male vs. female)	0.84	—	—	0.92	—	—
KPS (90-100 vs. 70-80)	0.002	0.008	1.48	0.001	0.005	1.57
RTOG-RPA group (III vs. IV vs. V)	<0.001	<0.001	1.98	<0.001	<0.001	2.14
Symptom duration (<3 vs. ≥3 months)	0.42	—	—	0.54	—	—
Extent of resection (GTR vs. STR/biopsy)	0.006	0.014	1.72	0.009	0.019	1.68
Pre-RT T2-FLAIR volume (<27 vs. ≥27 cc)	0.61	—	—	0.52	—	—
RT technique (3D-CRT vs. SIB-IMRT)	0.91	—	—	0.94	—	—
RT dose (60 vs. 70 Gy)	0.43	—	—	0.55	—	—
SII group (L-SII vs. H-SII)	<0.001	<0.001	2.07	<0.001	<0.001	2.77

PFS: progression-free survival; OS: overall survival; KPS: Karnofsky performance score; RTOG-RPA: Radiation Therapy Oncology Group recursive partitioning analysis; GTR: gross total resection; STR: subtotal resection; FLAIR: fluid attenuation inversion recovery; 3D-CRT: 3-dimensional conformal radiotherapy; SIB-IMRT: simultaneous integrated boost intensity-modulated radiotherapy; RT: radiotherapy; SII: systemic immune-inflammation index; L-SII: low-SII; H-SII: high-SII.